[Application of the fusafungine in perioperative period in patients after tonsillectomy].
The only treatment method in chronic palatine tonsillitis is the removal of tonsils (tonsillectomy). The study aimed at a clinical evaluation of postoperative fusafungine use in patients who underwent tonsillectomy. The study included 200 patients who underwent tonsillectomy for chronic palatine pyotonsillitis in the Otolaryngology Clinic of the Military Institute for the Health Services in Warsaw between 2000 and 2002. The patients were divided into two groups, each group including 100 patients: group I--patients who underwent tonsillectomy, including 67 females and 33 males, aged 16 to 52 (mean age 34.8), in whom fusafungine was used; group II--patients who underwent tonsillectomy, including 58 females and 42 males, aged 17 to 56 (mean age 36.1), who did not receive fusafungine. The subjects were observed during the first 14 days following the operation. The treatment was administered from the first day after the operation, by spraying 4 doses into the throat, 4 times a day, at 8.00 hrs, 12.00 hrs, 16.00 hrs and 20.00 hrs. The two groups were then compared in terms of: symptoms of sore throat, body temperature, swallowing difficulties, the course of healing, appearance of the pharyngeal mucosa, quality of life and general affection. Post-tonsillectomy fusafungine use was found to improve the patients' quality of life, appeases the sore throat and swallowing difficulties, decreases the need for general antibiotic therapy; the above results are statistically significant. Fusafungine was not found to influence body temperature, the appearance of the pharyngeal mucosa or the healing process.
Jurkiewicz
Dariusz
D
Wojskowy Instytut Medyczny, Klinika Otolaryngologii CSK MON w Warszawie.
Wojdas
Andrzej
A
Rapiejko
Piotr
P
Kantor
Ireneusz
I
Hermanowski
Maciej
M
Usowski
Jacek
J
Kenig
Dagmara
D
Grohulska
Ewa
E
D000293:Adolescent; D000328:Adult; D000336:Aerosols / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D047630:Depsipeptides; D005260:Female; D005670:Fusarium; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D014068:Tonsillectomy; D014069:Tonsillitis / Q000601:surgery*
D000336:Aerosols; D000900:Anti-Bacterial Agents; D047630:Depsipeptides; C014001:fusafungin